Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 5/2013

01-10-2013 | Research Article

Adverse drug events in surgical patients: an observational multicentre study

Authors: Monica de Boer, Eveline B. Boeker, Maya A. Ramrattan, Jordy J. S. Kiewiet, Marcel G. W. Dijkgraaf, Marja A. Boermeester, Loraine Lie-A-Huen

Published in: International Journal of Clinical Pharmacy | Issue 5/2013

Login to get access

Abstract

Background Errors occurring during different steps of the medication process can lead to adverse drug events (ADEs). Surgical patients are expected to have an increased risk for ADEs during hospitalization. However, detailed information about ADEs in the surgical patient is lacking. Objective In this study, we aim to measure the incidence and nature of (preventable) ADEs, potential risk factors for and outcome parameters of (preventable) ADEs in surgical patients. Setting Observational multicentre cohort study in which eight surgical wards participated from three Dutch hospitals, all using computerized physician order entry (CPOE) systems with clinical decision support. Methods Electively admitted surgical patients of the participating wards were included from March until June 2009. ADEs were measured using a standardized method with expert judgment. Incidence, severity, preventability and accountable medication were assessed. Poisson regression analysis was applied to determine the associations between possible risk factors and the occurrence of ADEs, expressed as incidence rate ratio (IRR). Also outcomes of ADEs in surgical patients were measured. Main outcome measure The incidence and nature of (preventable) ADEs in surgical patients. Results A total of 567 surgical patients were included. We found an incidence of 27.5 ADEs and 4.2 preventable ADEs (pADEs) per 100 admissions (15.4 %). A quarter of the pADEs were severe or life-threatening. Opioids and anti-coagulation medication play a major role in the occurrence of ADEs and pADEs respectively. Univariate analysis revealed an American Society of Anesthesiologists classification of III or more as a risk factor for ADEs. Patients older than 65 years [IRR 2.77 (1.14–6.72)], with cardiovascular comorbidity [IRR 2.87 (1.13–7.28)], or undergoing vascular surgery [IRR 2.32 (1.01–5.32)] were at risk for pADEs. Patients experiencing an ADE had a significant longer duration of admission than patients without an ADE. Conclusions Surgical patients are at considerable risk of experiencing one or more ADEs during their admission, also in CPOE-hospitals. Risk factors for pADEs are age older than 65 years, cardiovascular comorbidity, and vascular surgery. Intensified monitoring may be needed in patients with a higher than average risk for pADEs.
Literature
1.
go back to reference Leape LL, Brennan TA, Laird N, Lawthers AG, Localio AR, Barnes BA, et al. The nature of adverse events in hospitalized patients. Results of the Harvard Medical Practice Study II. N Engl J Med. 1991;324(6):377–84.PubMedCrossRef Leape LL, Brennan TA, Laird N, Lawthers AG, Localio AR, Barnes BA, et al. The nature of adverse events in hospitalized patients. Results of the Harvard Medical Practice Study II. N Engl J Med. 1991;324(6):377–84.PubMedCrossRef
2.
go back to reference Morimoto T, Gandhi TK, Seger AC, Hsieh TC, Bates DW. Adverse drug events and medication errors: detection and classification methods. Qual Saf Health Care. 2004;13(4):306–14.PubMedCrossRef Morimoto T, Gandhi TK, Seger AC, Hsieh TC, Bates DW. Adverse drug events and medication errors: detection and classification methods. Qual Saf Health Care. 2004;13(4):306–14.PubMedCrossRef
3.
go back to reference Cano FG, Rozenfeld S. Adverse drug events in hospitals: a systematic review. Cad saude publica. 2009;25(3):360–72. Cano FG, Rozenfeld S. Adverse drug events in hospitals: a systematic review. Cad saude publica. 2009;25(3):360–72.
4.
go back to reference Kanjanarat P, Winterstein AG, Johns TE, Hatton RC, Gonzalez-Rothi R, Segal R. Nature of preventable adverse drug events in hospitals: a literature review. Am J Health Syst Pharm. 2003;60(17):1750–9.PubMed Kanjanarat P, Winterstein AG, Johns TE, Hatton RC, Gonzalez-Rothi R, Segal R. Nature of preventable adverse drug events in hospitals: a literature review. Am J Health Syst Pharm. 2003;60(17):1750–9.PubMed
5.
go back to reference de Vries EN, Ramrattan MA, Smorenburg SM, Gouma DJ, Boermeester MA. The incidence and nature of in-hospital adverse events: a systematic review. Qual Saf Health Care. 2008;17(3):216–23.PubMedCrossRef de Vries EN, Ramrattan MA, Smorenburg SM, Gouma DJ, Boermeester MA. The incidence and nature of in-hospital adverse events: a systematic review. Qual Saf Health Care. 2008;17(3):216–23.PubMedCrossRef
6.
go back to reference Bates DW, Miller EB, Cullen DJ, Burdick L, Williams L, Laird N, et al. Patient risk factors for adverse drug events in hospitalized patients. ADE Prevention Study Group. Arch Intern Med. 1999;159(21):2553–60.PubMedCrossRef Bates DW, Miller EB, Cullen DJ, Burdick L, Williams L, Laird N, et al. Patient risk factors for adverse drug events in hospitalized patients. ADE Prevention Study Group. Arch Intern Med. 1999;159(21):2553–60.PubMedCrossRef
7.
go back to reference de Vries EN, Prins HA, Crolla RMPH, den Outer AJ, van Andel G, van Helden SH, et al. Effect of a comprehensive surgical safety system on patient outcomes. N Engl J Med. 2010;363(20):1928–37.PubMedCrossRef de Vries EN, Prins HA, Crolla RMPH, den Outer AJ, van Andel G, van Helden SH, et al. Effect of a comprehensive surgical safety system on patient outcomes. N Engl J Med. 2010;363(20):1928–37.PubMedCrossRef
8.
go back to reference Lazarus HM, Fox J, Evans RS, Lloyd JF, Pombo DJ, Burke JP, et al. Adverse drug events in trauma patients. J Trauma. 2003;54(2):337–43.PubMedCrossRef Lazarus HM, Fox J, Evans RS, Lloyd JF, Pombo DJ, Burke JP, et al. Adverse drug events in trauma patients. J Trauma. 2003;54(2):337–43.PubMedCrossRef
9.
go back to reference Morimoto T, Sakuma M, Matsui K, Kuramoto N, Toshiro J, Murakami J, et al. Incidence of adverse drug events and medication errors in Japan: the JADE study. J Gen Inter Med. 2011;26(2):148–53.CrossRef Morimoto T, Sakuma M, Matsui K, Kuramoto N, Toshiro J, Murakami J, et al. Incidence of adverse drug events and medication errors in Japan: the JADE study. J Gen Inter Med. 2011;26(2):148–53.CrossRef
10.
go back to reference Bates DW, Cullen DJ, Laird N, Petersen LA, Small SD, Servi D, et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA. 1995;274(1):29–34.PubMedCrossRef Bates DW, Cullen DJ, Laird N, Petersen LA, Small SD, Servi D, et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA. 1995;274(1):29–34.PubMedCrossRef
11.
go back to reference Berga C, Gorgas Torner M, Altimiras R, Tuset CM, Besalduch MM, Capdevilla SM, et al. Detecting adverse drug events during hospital stay. Farm Hosp. 2009;33(6):312–23.CrossRef Berga C, Gorgas Torner M, Altimiras R, Tuset CM, Besalduch MM, Capdevilla SM, et al. Detecting adverse drug events during hospital stay. Farm Hosp. 2009;33(6):312–23.CrossRef
12.
go back to reference Nebeker JR, Hoffman JM, Weir CR, Bennet CL, Hurdle JF. High rates of adverse drug events in a highly computerized hospital. Arch Intern Med. 2005;165(10):1111–6.PubMedCrossRef Nebeker JR, Hoffman JM, Weir CR, Bennet CL, Hurdle JF. High rates of adverse drug events in a highly computerized hospital. Arch Intern Med. 2005;165(10):1111–6.PubMedCrossRef
13.
go back to reference de Boer M, Kiewiet JJS, Boeker EB, Ramrattan MA, Dijkgraaf MGW, Lie-A-Huen L, et al. A targeted method for standardized assessment of adverse drug events in surgical patients. J Eval Clin Pract 2013 [Epub ahead of print]. de Boer M, Kiewiet JJS, Boeker EB, Ramrattan MA, Dijkgraaf MGW, Lie-A-Huen L, et al. A targeted method for standardized assessment of adverse drug events in surgical patients. J Eval Clin Pract 2013 [Epub ahead of print].
15.
16.
go back to reference Cullen DJ, Sweitzer BJ, Bates DW, Burdick E, Edmondson A, Leape LL. Preventable adverse drug events in hospitalized patients: a comparative study of intensive care and general care units. Crit Care Med. 1997;25(8):1289–97.PubMedCrossRef Cullen DJ, Sweitzer BJ, Bates DW, Burdick E, Edmondson A, Leape LL. Preventable adverse drug events in hospitalized patients: a comparative study of intensive care and general care units. Crit Care Med. 1997;25(8):1289–97.PubMedCrossRef
18.
go back to reference de Boer M, Ramrattan MA, Kiewiet JJ, Boeker EB, Gombert-Handoko KB, van Lent-Evers NAEM, et al. Cost-effectiveness of ward-based pharmacy care in surgical patients: protocol of the SUREPILL (Surgery & Pharmacy In Liaison) study. BMC Health Serv Res. 2011;11(1):55.PubMedCrossRef de Boer M, Ramrattan MA, Kiewiet JJ, Boeker EB, Gombert-Handoko KB, van Lent-Evers NAEM, et al. Cost-effectiveness of ward-based pharmacy care in surgical patients: protocol of the SUREPILL (Surgery & Pharmacy In Liaison) study. BMC Health Serv Res. 2011;11(1):55.PubMedCrossRef
Metadata
Title
Adverse drug events in surgical patients: an observational multicentre study
Authors
Monica de Boer
Eveline B. Boeker
Maya A. Ramrattan
Jordy J. S. Kiewiet
Marcel G. W. Dijkgraaf
Marja A. Boermeester
Loraine Lie-A-Huen
Publication date
01-10-2013
Publisher
Springer Netherlands
Published in
International Journal of Clinical Pharmacy / Issue 5/2013
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-013-9797-5

Other articles of this Issue 5/2013

International Journal of Clinical Pharmacy 5/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine